All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @charlotte16a on TikTok · 94s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @charlotte16a's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Okay, so this is my last and final attempt at trying to warn people about
  2. 0:06Manjaro. It's come to this point now where I can't take it anymore and I try
  3. 0:13to warn people no one listens and now this has happened. Yes it's fantastic
  4. 0:20for losing weight but I've just done think people are taking the side effects
  5. 0:23seriously. Ever since I started taking Manjaro it's been really effective I've
  6. 0:29lost weight I've lost 36 pounds now but I've worn people in other videos and many
  7. 0:37people see them and a lot of people took my advice but okay I'll just show you
  8. 0:43right. So my engagement ring has now got so big that it's had to move up a finger
  9. 0:51and my wedding band moved off his finger and up and now everywhere I go people
  10. 0:57just call me sexy and they try to they try to cop on with me because they
  11. 1:03don't they don't know I'm married now so what can I do? All the time can't call
  12. 1:10me and I've lost so much money I've had to throw out so many clothes because I'm
  13. 1:17so skinny now that none of my clothes fit me and I've got to replace them all.
  14. 1:23What can I do? But there we are I've tried to warn you listen if you want.

@charlotte16a's Mounjaro weight loss claims, fact-checked

charlotte16a

TikTok creator

3.0M viewsWatch on TikTok

Quick answer

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and, under the brand name Zepbound, for chronic weight management. The SURMOUNT-1 trial (Jastreboff et al., 2022) documented mean weight loss of up to 20.9% at 72 weeks, making a 36-pound loss consistent with published outcomes. Real adverse effects documented in trial data include gastrointestinal symptoms in the majority of users, a boxed warning for thyroid C-cell tumors based on animal data, and elevated rates of gallbladder disease and pancreatitis.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksTirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @charlotte16a's Mounjaro weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@charlotte16a's Mounjaro weight loss claims, fact-checked" from charlotte16a. We read the clip as a GLP-1 social video fact-checks claim about Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and, under the brand name Zepbound, for chronic weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 mounjaroweightloss mounjaro mounjarojourney weightloss." In this clip, the useful excerpt is: "Okay, so this is my last and final attempt at trying to warn people about Manjaro." That wording changes the review because it points to Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

This video is comedy, not a medical warning.
People who land here are usually comparing the Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and, under the brand name Zepbound, for chronic weight management.

FormBlends verdict

Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and, under the brand name Zepbound, for chronic weight management. The SURMOUNT-1 trial (Jastreboff et al., 2022) documented mean weight loss of up to 20.9% at 72 weeks, making a 36-pound loss consistent with published outcomes. Real adverse effects documented in trial data include gastrointestinal symptoms in the majority of users, a boxed warning for thyroid C-cell tumors based on animal data, and elevated rates of gallbladder disease and pancreatitis.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% mean body weight loss on tirzepatide at 72 weeks, making a 36-pound loss entirely realistic.
  • This video is comedy, not a medical warning. The 'side effects' described are weight loss outcomes, not adverse events.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% mean body weight loss on tirzepatide at 72 weeks, making a 36-pound loss entirely realistic.
  • This video is comedy, not a medical warning. The 'side effects' described are weight loss outcomes, not adverse events.
  • Real tirzepatide adverse effects include nausea (majority of users), vomiting, diarrhea, and a boxed FDA warning for thyroid C-cell tumors based on animal data.
  • SURMOUNT-4 (Aronne et al., 2024, JAMA) found approximately two-thirds of lost weight is regained within one year of stopping tirzepatide.
  • Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Formulation and sterility standards are not the same.
  • Muscle mass loss during rapid weight loss on GLP-1 class drugs is a documented concern. Adequate protein intake and resistance training are standard clinical recommendations to reduce this risk.
  • Tirzepatide is a prescription medication requiring medical supervision. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @charlotte16a actually say?

This video is a comedic bait-and-switch, not a genuine safety warning. Charlotte frames it as a desperate final attempt to "warn people about Mounjaro" before revealing her "side effects" are a loose engagement ring, unwanted male attention, and a wardrobe that no longer fits because she has lost 36 pounds. There is no actual medical claim being made here. It is a joke.

To be clear: she is not warning viewers about gastroparesis, pancreatitis, or thyroid tumors. She is complaining, tongue-in-cheek, that weight loss works too well. The transcript ends with "if you want," which is the punchline. Treating this as a genuine medical claim would be a misread of the content. That said, 3 million people watched it, and some may come away with genuine questions about what Mounjaro actually does, so those questions are worth answering seriously.

Does the science back up losing 36 pounds on tirzepatide?

Yes, and then some. Losing 36 pounds on tirzepatide (Mounjaro's active ingredient) is entirely consistent with clinical data. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on the highest dose of tirzepatide lost an average of 20.9% of body weight over 72 weeks, which in a 200-pound person would be roughly 42 pounds.

The mechanism is dual: tirzepatide activates both GLP-1 and GIP receptors, which together suppress appetite more aggressively than GLP-1 agonists like semaglutide alone. Participants in SURMOUNT-1 also reported significant reductions in caloric intake driven by reduced hunger and slowed gastric emptying. So yes, rings getting loose and clothes becoming unwearable are realistic outcomes. The joke is grounded in real physiology, even if the framing is satirical.

What did Charlotte get wrong, and what did she get right?

She got the weight loss part right. A 36-pound loss is plausible and well within the range documented in trials. She also implicitly got something right that many creators miss: she combined Mounjaro with a calorie deficit, which her hashtags confirm. Tirzepatide is not a passive drug. The evidence consistently shows better outcomes when behavioral changes accompany it.

What she arguably undersells, though unintentionally, is that real Mounjaro side effects exist and are not funny. The FDA label includes a boxed warning for thyroid C-cell tumors observed in animal studies. Common adverse events include nausea, vomiting, diarrhea, and constipation, reported in 12 to 18% of participants in SURMOUNT-1. Acute pancreatitis is a rare but serious risk. Gallbladder disease is also elevated in rapid weight loss contexts. None of that appears in this video, and 3 million impressions is a lot of reach to not have that context anywhere nearby.

What should you actually know about tirzepatide and weight loss?

If you are considering Mounjaro or its weight-loss-indicated equivalent Zepbound (same active ingredient, different FDA approval), a few things are worth knowing that this video does not cover.

  • Tirzepatide requires a prescription and ongoing medical supervision. It is not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
  • Weight regain is documented after stopping the drug. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) found participants regained about two-thirds of lost weight within one year of discontinuation.
  • Muscle mass loss is a real concern during rapid weight loss on GLP-1 class drugs. Adequate protein intake and resistance training are consistently recommended by prescribing clinicians to mitigate this.
  • Compounded tirzepatide is not the same as FDA-approved Mounjaro or Zepbound. Formulation, dosing accuracy, and sterility standards differ. Do not assume equivalency.
  • Side effects that are not funny: nausea affects a majority of users at some point, and for some people it is severe enough to require dose reduction or discontinuation.

Charlotte's video is harmless satire. But the comment section of a 3-million-view video is where real misconceptions form, and "the side effects are just that you get too skinny" is not a complete picture.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

charlotte16a · TikTok creator

3.0M views on this video

#mounjaroweightloss #mounjaro #mounjarojourney #weightloss #caloriedeficit

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) documented up to 20.9%?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented up to 20.9% mean body weight loss on tirzepatide at 72 weeks, making a 36-pound loss entirely realistic.

What does the video say about this video?

This video is comedy, not a medical warning. The 'side effects' described are weight loss outcomes, not adverse events.

What does the video say about real tirzepatide adverse effects include nausea (majority of users), vomiting,?

Real tirzepatide adverse effects include nausea (majority of users), vomiting, diarrhea, and a boxed FDA warning for thyroid C-cell tumors based on animal data.

What does the video say about surmount-4 (aronne et al., 2024, jama) found approximately two-thirds of?

SURMOUNT-4 (Aronne et al., 2024, JAMA) found approximately two-thirds of lost weight is regained within one year of stopping tirzepatide.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Formulation and sterility standards are not the same.

What does the video say about muscle mass loss during rapid weight loss on glp-1 class?

Muscle mass loss during rapid weight loss on GLP-1 class drugs is a documented concern. Adequate protein intake and resistance training are standard clinical recommendations to reduce this risk.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by charlotte16a, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.